You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Tisotumab vedotin

Showing 1 - 25 of 266
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Malignancies Trial (Tisotumab Vedotin)

Not yet recruiting
  • Solid Malignancies
  • Tisotumab Vedotin
  • (no location specified)
May 9, 2023

Ovary Cancer, Cervix Cancer, Endometrium Cancer Trial in United Kingdom, United States (Tisotumab Vedotin)

Completed
Has Results
  • Ovary Cancer
  • +7 more
  • Tisotumab Vedotin
  • Miami, Florida
  • +3 more
Oct 6, 2021

Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Trial in Worldwide (tisotumab vedotin)

Completed
  • Ovarian Cancer
  • +2 more
  • tisotumab vedotin
  • San Jose, California
  • +36 more
Jul 8, 2022

Cervical Cancer Trial in Worldwide (Tisotumab Vedotin, Bevacizumab, Pembrolizumab)

Active, not recruiting
  • Cervical Cancer
  • Tisotumab Vedotin
  • +3 more
  • Phoenix, Arizona
  • +71 more
Jan 9, 2023

Ovary Cancer, Cervix Cancer, Endometrium Cancer Trial in Worldwide (Tisotumab Vedotin (HuMax-TF-ADC))

Completed
Has Results
  • Ovary Cancer
  • +7 more
  • Tisotumab Vedotin (HuMax-TF-ADC)
  • Orange, California
  • +28 more
Nov 29, 2021

Ovary Cancer, Cervix Cancer, Endometrium Cancer Trial in Worldwide (Tisotumab vedotin (HuMax-TF-ADC))

Completed
Has Results
  • Ovary Cancer
  • +6 more
  • Tisotumab vedotin (HuMax-TF-ADC)
  • Houston, Texas
  • +15 more
Mar 15, 2021

Cervical Cancer Trial in Worldwide (tisotumab vedotin, topotecan, vinorelbine)

Recruiting
  • Cervical Cancer
  • tisotumab vedotin
  • +5 more
  • Birmingham, Alabama
  • +138 more
Aug 15, 2022

Reporting of Antibody-Drug Conjugate Associated Sepsis-related

Completed
  • Sepsis (SMQ)
  • +2 more
  • Antibody-Drug Conjugate
  • Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
  • Changsha, Hunan, China
    Central South University
Jun 19, 2022

Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8 Trial in Phoenix,

Not yet recruiting
  • Metastatic Penile Squamous Cell Carcinoma
  • +3 more
  • Enfortumab Vedotin
  • Phoenix, Arizona
  • +2 more
Oct 23, 2023

DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 5, 2023

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Capecitabine, oxaliplatin, Disitamab Vedotin)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Beijing, Beijing, China
  • +10 more
Nov 23, 2023

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)

Not yet recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Biopsy
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023

Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Tumor Trial in Atlanta (procedure,

Not yet recruiting
  • Bladder Squamous Cell Carcinoma
  • +10 more
  • Biospecimen Collection
  • +5 more
  • Atlanta, Georgia
  • +3 more
Feb 20, 2023

Breast Cancer Trial in Nanjing (Disitamb Vedotin ,pyrotinib)

Not yet recruiting
  • Breast Cancer
  • Disitamb Vedotin ,pyrotinib
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Aug 18, 2023

Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48 Trial in Guanzhou (RC48+Tislelizumab+carboplatin,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • Guanzhou, China
    SunYat-senU
May 5, 2023

Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate

Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +8 more
  • Polatuzumab Vedotin
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Cutaneous T-cell Lymphoma Retreated With Brentuximab Vedotin

Not yet recruiting
  • T-Cell Lymphoma
  • No intervention
  • Bordeaux, France
  • +10 more
May 24, 2023

Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma Trial in United States (brentuximab vedotin)

Terminated
  • Hodgkin Lymphoma
  • +2 more
  • brentuximab vedotin
  • Anaheim, California
  • +18 more
Dec 6, 2022

RC48-ADC in Breast Cancer

Not yet recruiting
  • Breast Cancer
  • Disitamab vedotin
  • (no location specified)
Apr 30, 2023

Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Richter's Transformation
  • Boston, Massachusetts
  • +1 more
Sep 12, 2023

Breast Cancer Trial in Xi'an (Disitamab Vedotin plus pyrotinib or naratinib)

Not yet recruiting
  • Breast Cancer
  • Disitamab Vedotin plus pyrotinib or naratinib
  • Xi'an, Shaanxi, China
    Xi'an International Medical Center Hospital
Aug 27, 2023

Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic

Recruiting
  • Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
  • +3 more
  • Cabozantinib S-malate
  • +3 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Aug 8, 2022

Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer Trial in Kansas City (Enfortumab vedotin)

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +2 more
  • Enfortumab vedotin
  • Kansas City, Kansas
    University of Kansas Cancer Center
Jun 23, 2023

Gastric Cancer Trial (Disitamab Vedotin combined with Sintilimab)

Not yet recruiting
  • Gastric Cancer
  • Disitamab Vedotin combined with Sintilimab
  • (no location specified)
Jul 2, 2023

Advanced Classical Hodgkin's Lymphoma in Brazil Treated With

Not yet recruiting
  • Hodgkin Lymphoma
  • No Intervention
  • Salvador, Bahia, Brazil
  • +5 more
Oct 23, 2023